Cover Image
市場調查報告書

美國的Port Needle市場分析

US Market Report for Port Needles - MedCore

出版商 iData Research Inc. 商品編碼 360658
出版日期 內容資訊 英文 168 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的Port Needle市場分析 US Market Report for Port Needles - MedCore
出版日期: 2016年05月01日 內容資訊: 英文 168 Pages
簡介

本報告提供美國的Port Needle (植入端口針頭)的市場相關分析,市場背景情況 (相關疾病與其患病人數等) ,及整體整體市場規模的變化及預測 (過去4年、今後7年份),各治療內容、各分類的詳細趨勢等調查、估計,主要企業簡介與產品結構,近幾年的企業間競爭情勢等資訊彙整,為您概述為以下內容。

摘要整理

分析方法

  • 分析範圍
  • IDATA的9階段的分析方法

疾病概要

  • 解剖學性的基礎結構
    • 人的血管系統
  • 血管的病理與疾病
    • 癌症
    • 末期腎功能衰竭
    • 糖尿病
  • 患者的人口組成
    • 癌症 (共15種)
    • 末期腎功能衰竭
      • 發病數量 (各種模式,各年齡層等)
      • 人工透析開始時使用的血管通路手段
      • 患病人數 (各種模式,各年齡層等)
    • 糖尿病
      • 已受診的成人發病數量 (各州)
      • 已受診的成人患病人數 (各重症度,各年齡層,男女,各州)

產品的評估

  • 產品系列
    • Port Needle
      • 簡介
      • AngioDynamics (共2項產品)
      • B. Braun (共1項產品)
      • Cook Medical (共1項產品)
      • C. R. Bard (共2項產品)
      • 川澄化學工業 (共2項產品)
      • MPS Medical, Inc. (共1項產品)
      • Nipro Medical (共1項產品)
      • Smiths Medical (共3項產品)
      • Vygon (Churchill Medical Systems) (共2項產品)

Port Needle市場

  • 簡介
    • 各設定
    • 設備的各類型
  • 市場分析與預測
    • Port Needle整體市場
    • 急救治療用Port Needle的市場
      • 傳統Port Needle
      • 附安全功能Port Needle
        • 高壓注射式
        • 其他
    • 替代治療用Port Needle的市場
      • 傳統Port Needle
      • 附安全功能Port Needle
        • 高壓注射式
        • 其他
  • 推動及阻礙市場要素
    • 推動市場要素
    • 阻礙市場要素
  • 市場競爭、市場佔有率分析

圖表一覽

目錄
Product Code: iDATA_USVA16_MC_PN

The total U.S market for port needles can be segmented by care setting, yielding two segments: the acute care segment and the alternate care segment. In 2015, the largest segment in the total port needle market was the alternate care segment, the segment represented over 60% of the total market value.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1. U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
  • 1.2. COMPETITIVE LANDSCAPE
  • 1.3. MARKET TRENDS
  • 1.4. KEY MARKET DEVELOPMENTS
  • 1.5. MARKETS INCLUDED
  • 1.6. PROCEDURES INCLUDED
  • 1.7. PROCEDURE CODES INVESTIGATED
  • 1.8. KEY REPORT UPDATES
  • 1.9. VERSION HISTORY

RESEARCH METHODOLOGY

  • 2.1. RESEARCH SCOPE
  • 2.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 3.1. BASIC ANATOMY
    • 3.1.1. Human Vascular System
  • 3.2. VASCULAR PATHOLOGY AND DISORDERS
    • 3.2.1. Cancer
    • 3.2.2. End-Stage Renal Disease
    • 3.2.3. Diabetes
  • 3.3. PATIENT DEMOGRAPHICS
    • 3.3.1. Cancer
      • 3.3.1.1. Digestive Cancer
      • 3.3.1.2. Genital Cancer
      • 3.3.1.3. Breast Cancer
      • 3.3.1.4. Respiratory Cancer
      • 3.3.1.5. Urinary Cancer
      • 3.3.1.6. Skin Cancer
      • 3.3.1.7. Lymphoma
      • 3.3.1.8. Endocrine System Cancer
      • 3.3.1.9. Leukemia
      • 3.3.1.10. Oral Cavity/Larynx
      • 3.3.1.11. Myeloma
      • 3.3.1.12. Brain/Other Nervous System
      • 3.3.1.13. Soft Tissue (including heart)
      • 3.3.1.14. Bones and Joints
      • 3.3.1.15. Eye and Orbit
    • 3.3.2. End-Stage Renal Disease
      • 3.3.2.1. End-Stage Renal Disease Incidence
        • 3.3.2.1.1. End-Stage Renal Disease Incident Cases by Modality
        • 3.3.2.1.2. End-Stage Renal Disease Incident Cases by Age Group
        • 3.3.2.1.3. End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
      • 3.3.2.2. Vascular Access Use at Hemodialysis Initiation
        • 3.3.2.2.1. Vascular Access Use During First Year of Hemodialysis
          • 3.3.2.2.1.1. Vascular Access Use During First Year of Hemodialysis by Age Group
          • 3.3.2.2.1.2. Vascular Access Use During First Year of Hemodialysis by Sex
      • 3.3.2.3. End-Stage Renal Disease Prevalence
        • 3.3.2.3.1. End-Stage Renal Disease Prevalent Cases by Modality
          • 3.3.2.3.1.1. Prevalent Hemodialysis Patients by Vascular Access Type
        • 3.3.2.3.2. End-Stage Renal Disease Prevalent Cases by Age Group
        • 3.3.2.3.3. End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
    • 3.3.3. Diabetes
      • 3.3.3.1. Diagnosed Diabetes Incidence Amongst Adults
        • 3.3.3.1.1. Diagnosed Diabetes Incidence Amongst Adults by State
      • 3.3.3.2. Diagnosed Diabetes Prevalence Amongst Adults
        • 3.3.3.2.1. Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
        • 3.3.3.2.2. Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
        • 3.3.3.2.3. Diagnosed Diabetes Prevalence Amongst Adults by State and Gender

PRODUCT ASSESSMENT

  • 4.1. PRODUCT PORTFOLIOS
    • 4.1.1. Port Needles
      • 4.1.1.1. Introduction
      • 4.1.1.2. AngioDynamics
        • 4.1.1.2.1. LifeGuard®
        • 4.1.1.2.2. LifePort®
      • 4.1.1.3. B. Braun
        • 4.1.1.3.1. WHIN®
      • 4.1.1.4. Cook Medical
        • 4.1.1.4.1. Vital-Ject™
      • 4.1.1.5. C. R. Bard
        • 4.1.1.5.1. PowerLoc®
        • 4.1.1.5.2. Other Port Needle Offerings
      • 4.1.1.6. Kawasumi
        • 4.1.1.6.1. K-Shield®
        • 4.1.1.6.2. Other Port Needle Offerings
      • 4.1.1.7. MPS Medical, Inc.
        • 4.1.1.7.1. SmartSafety®
      • 4.1.1.8. Nipro Medical
        • 4.1.1.8.1. SafeTouch™
      • 4.1.1.9. Smiths Medical
        • 4.1.1.9.1. GRIPPER®
        • 4.1.1.9.2. GRIPPER PLUS®
        • 4.1.1.9.3. Other Port Needle Offerings
      • 4.1.1.10. Vygon (Churchill Medical Systems)
        • 4.1.1.10.1. LifeGuard™
        • 4.1.1.10.2. Wing Safe™

PORT NEEDLE MARKET

  • 5.1. MARKET OVERVIEW
    • 5.1.1. Port Needle Market Overview by Setting
    • 5.1.2. Port Needle Market Overview by Device Type
  • 5.2. MARKET ANALYSIS AND FORECAST
    • 5.2.1. Total Port Needle Market
    • 5.2.2. Total Acute Care Port Needle Market
      • 5.2.2.1. Acute Care Conventional Port Needle Market
      • 5.2.2.2. Total Acute Care Safety Port Needle Market
        • 5.2.2.2.1. Acute Care Safety Power-Injectable Port Needle Market
        • 5.2.2.2.2. Acute Care Safety Non-Power-Injectable Port Needle Market
      • 5.2.3. Total Alternate Care Port Needle Market
        • 5.2.3.1. Alternate Care Conventional Port Needle Market
        • 5.2.3.2. Total Alternate Care Safety Port Needle Market
          • 5.2.3.2.1. Alternate Care Safety Power-Injectable Port Needle Market
          • 5.2.3.2.2. Alternate Care Safety Non-Power-Injectable Port Needle Market
  • 5.3. DRIVERS AND LIMITERS
    • 5.3.1. Market Drivers
    • 5.3.2. Market Limiters
  • 5.4. COMPETITIVE MARKET SHARE ANALYSIS

LIST OF CHARTS

  • Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012-2022
  • Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
  • Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
  • Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
  • Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
  • Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
  • Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
  • Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
  • Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
  • Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
  • Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
  • Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
  • Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-28: Male Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015 83
  • Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Chart 3-61: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Chart 5-1: Port Needle Market by Setting, U.S., 2012-2022
  • Chart 5-2: Port Needle Market Breakdown by Setting, U.S., 2015
  • Chart 5-3: Port Needle Market Breakdown by Setting, U.S., 2022
  • Chart 5-4: Port Needle Market by Device, U.S., 2012-2022
  • Chart 5-5: Port Needle Market Breakdown by Device Type, U.S., 2015
  • Chart 5-6: Port Needle Market Breakdown by Device Type, U.S., 2022
  • Chart 5-7: Total Port Needle Market, U.S., 2012-2022
  • Chart 5-8: Total Acute Care Port Needle Market, U.S., 2012-2022
  • Chart 5-9: Acute Care Conventional Port Needle Market, U.S., 2012-2022
  • Chart 5-10: Total Acute Care Safety Port Needle Market, U.S., 2012-2022
  • Chart 5-11: Acute Care Safety Power-Injectable Port Needle Market, U.S., 2012-2022
  • Chart 5-12: Acute Care Safety Non-Power-Injectable Port Needle Market, U.S., 2012-2022
  • Chart 5-13: Total Alternate Care Port Needle Market, U.S., 2012-2022
  • Chart 5-14: Alternate Care Conventional Port Needle Market, U.S., 2012-2022
  • Chart 5-15: Total Alternate Care Safety Port Needle Market, U.S., 2012-2022
  • Chart 5-16: Alternate Care Safety Power-Injectable Port Needle Market, U.S., 2012-2022
  • Chart 5-17: Alternate Care Safety Non-Power-Injectable Port Needle Market, U.S., 2012-2022
  • Chart 5-18: Leading Competitors, Port Needle Market, U.S., 2015

LIST OF FIGURES

  • Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
  • Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
  • Figure 0-3: Companies Researched in Report, U.S., 2015
  • Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
  • Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012-2015
  • Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
  • Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
  • Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
  • Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
  • Figure 0-10: Procedural Codes, U.S., 2015
  • Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
  • Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
  • Figure 0-13: Version History
  • Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
  • Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013-2014
  • Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013-2014
  • Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
  • Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
  • Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997-2015
  • Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
  • Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
  • Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
  • Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
  • Figure 5-1: Port Needle Market by Setting, U.S., 2012-2022 (US$M)
  • Figure 5-2: Port Needle Market by Device Type, U.S., 2012-2022 (US$M)
  • Figure 5-3: Total Port Needle Market, U.S., 2012-2022
  • Figure 5-4: Total Acute Care Port Needle Market, U.S., 2012-2022
  • Figure 5-5: Acute Care Conventional Port Needle Market, U.S., 2012-2022
  • Figure 5-6: Total Acute Care Safety Port Needle Market, U.S., 2012-2022
  • Figure 5-7: Acute Care Safety Power-Injectable Port Needle Market, U.S., 2012-2022
  • Figure 5-8: Acute Care Safety Non-Power-Injectable Port Needle Market, U.S., 2012-2022
  • Figure 5-9: Total Alternate Care Port Needle Market, U.S., 2012-2022
  • Figure 5-10: Alternate Care Conventional Port Needle Market, U.S., 2012-2022
  • Figure 5-11: Total Alternate Care Safety Port Needle Market, U.S., 2012-2022
  • Figure 5-12: Alternate Care Safety Power-Injectable Port Needle Market, U.S., 2012-2022
  • Figure 5-13: Alternate Care Safety Non-Power-Injectable Port Needle Market, U.S., 2012-2022
  • Figure 5-14: Drivers and Limiters, Port Needle Market, U.S., 2015
  • Figure 5-15: Leading Competitors, Port Needle Market, U.S., 2015
Back to Top